{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:38:19Z","timestamp":1781059099654,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard of care (SOC) with SOC alone in adults hospitalized with COVID-19 requiring oxygen support in the early stage of the pandemic.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data for 10-day remdesivir treatment plus SOC from the extension phase of an open-label study (NCT04292899) were compared with real-world, retrospective data on SOC alone (EUPAS34303). Both studies included patients aged \u226518 years hospitalized with severe acute respiratory syndrome coronavirus 2 up to 30 May 2020, with oxygen saturation \u226494% on room air or supplemental oxygen (all forms), and with pulmonary infiltrates. Propensity score weighting was used to balance patient demographics and clinical characteristics across treatment groups. The primary endpoint was time to all-cause mortality or end of study (day 28). Time to discharge, with a 10-day landmark to account for duration of remdesivir treatment, was a secondary endpoint.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1974 patients treated with remdesivir plus SOC, and 1426 with SOC alone, were included after weighting. Remdesivir significantly reduced mortality versus SOC (hazard ratio [HR], 0.46; 95% confidence interval, .39\u2013.54). This association was observed at each oxygen support level, with the lowest HR for patients on low-flow oxygen. Remdesivir significantly increased the likelihood of discharge at day 28 versus SOC in the 10-day landmark analysis (HR, 1.64; 95% confidence interval: 1.43\u20131.87).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Remdesivir plus early-2020 SOC was associated with a 54% lower mortality risk and shorter hospital stays compared with SOC alone in patients hospitalized with COVID-19 requiring oxygen support.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. \u00a0ClinicalTrials.gov NCT04292899 and EUPAS34303.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae336","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T12:12:01Z","timestamp":1719403921000},"page":"1182-1189","source":"Crossref","is-referenced-by-count":2,"title":["Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies"],"prefix":"10.1093","volume":"79","author":[{"given":"Dahlene","family":"Fusco","sequence":"first","affiliation":[{"name":"Department of Medicine , Tulane Medical Center, New Orleans, Louisiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-8088","authenticated-orcid":false,"given":"Ivana","family":"Malenica","sequence":"additional","affiliation":[{"name":"Real World Evidence, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]},{"name":"Department of Biostatistics, University of California , Berkeley, Berkeley, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-6723","authenticated-orcid":false,"given":"Huldrych F","family":"G\u00fcnthard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich , Zurich ,","place":["Switzerland"]},{"name":"Institute of Medical Virology, University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Indiana University School of Medicine , Indianapolis, Indiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dax","family":"Kurbegov","sequence":"additional","affiliation":[{"name":"Sarah Cannon, Nashville , Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Balani","sequence":"additional","affiliation":[{"name":"Hackensack School of Medicine, Hackensack University Medical Center , Hackensack, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Olender","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Columbia University in the City of New York , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A","family":"Aberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E","family":"Telep","sequence":"additional","affiliation":[{"name":"Real World Evidence, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics and Exploratory Analytics, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Blair","sequence":"additional","affiliation":[{"name":"Biostatistics, Gilead Sciences, Inc., Foster City , California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wu","sequence":"additional","affiliation":[{"name":"Biostatistics, Gilead Sciences, Inc., Foster City , California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"Haubrich","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-3033","authenticated-orcid":false,"given":"Anand P","family":"Chokkalingam","sequence":"additional","affiliation":[{"name":"Real World Evidence, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]},{"name":"Division of Epidemiology, School of Public Health, University of California , Berkeley, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu O","family":"Osinusi","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[{"name":"Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Center for Advanced Heart and Lung Disease, Baylor University Medical Center , Dallas, Texas ,","place":["USA"]},{"name":"Department of Internal Medicine, Texas A&M Health Science Center , Dallas, Texas ,","place":["USA"]},{"name":"Department of Internal Medicine, Burnett School of Medicine at TCU , Fort Worth, Texas ,","place":["USA"]},{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"2024112123540250800_ciae336-B1","author":"United States Food and Drug Administration"},{"key":"2024112123540250800_ciae336-B2","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciaa478","article-title":"Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19","volume":"78","author":"Bhimraj","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024112123540250800_ciae336-B3","author":"National Institutes of Health (US)"},{"key":"2024112123540250800_ciae336-B4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112123540250800_ciae336-B5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S1473-3099(22)00295-X","article-title":"Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024112123540250800_ciae336-B6","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"CMAJ"},{"key":"2024112123540250800_ciae336-B7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO solidarity randomised trial and updated meta-analyses","volume":"399","author":"WHO Solidarity Trial Consortium","year":"2022","journal-title":"Lancet"},{"key":"2024112123540250800_ciae336-B8","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024112123540250800_ciae336-B9","doi-asserted-by":"crossref","first-page":"e2114741","DOI":"10.1001\/jamanetworkopen.2021.14741","article-title":"Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19","volume":"4","author":"Ohl","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024112123540250800_ciae336-B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for COVID-19\u2014interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024112123540250800_ciae336-B11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"2024112123540250800_ciae336-B12","doi-asserted-by":"crossref","first-page":"S581","DOI":"10.1016\/j.jval.2022.04.1555","article-title":"RWD31 Comparison of remdesivir as monotherapy or in combination with steroids in treating COVID-19 patients","volume":"25","author":"Rawat","year":"2022","journal-title":"Value Health"},{"key":"2024112123540250800_ciae336-B13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"2024112123540250800_ciae336-B14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s15010-021-01671-0","article-title":"Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis","volume":"50","author":"Angamo","year":"2022","journal-title":"Infection"},{"key":"2024112123540250800_ciae336-B15","first-page":"CD014962","article-title":"Remdesivir for the treatment of COVID-19","volume":"1","author":"Grundeis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2024112123540250800_ciae336-B16","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1038\/s41598-022-13680-6","article-title":"Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis","volume":"12","author":"Beckerman","year":"2022","journal-title":"Sci Rep"},{"key":"2024112123540250800_ciae336-B17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.7326\/M21-4784","article-title":"Major update 2: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points","volume":"175","author":"Kaka","year":"2022","journal-title":"Ann Intern Med"},{"key":"2024112123540250800_ciae336-B18","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/jac\/dkab093","article-title":"Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials","volume":"76","author":"Lai","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024112123540250800_ciae336-B19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cmi.2022.04.018","article-title":"Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024112123540250800_ciae336-B20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/23744235.2021.1923799","article-title":"Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"53","author":"Okoli","year":"2021","journal-title":"Infect Dis (Lond)"},{"key":"2024112123540250800_ciae336-B21","doi-asserted-by":"crossref","first-page":"20420986211042517","DOI":"10.1177\/20420986211042517","article-title":"The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis","volume":"12","author":"Santenna","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"2024112123540250800_ciae336-B22","doi-asserted-by":"crossref","first-page":"e048416","DOI":"10.1136\/bmjopen-2020-048416","article-title":"Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2021","journal-title":"BMJ Open"},{"key":"2024112123540250800_ciae336-B23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14787210.2021.1949984","article-title":"The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review","volume":"20","author":"Thiruchelvam","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024112123540250800_ciae336-B24","doi-asserted-by":"crossref","first-page":"S605","DOI":"10.1016\/j.jval.2022.04.1671","article-title":"SA5 the effectiveness and safety of remdesivir for COVID-19: a quantitative meta-analysis","volume":"25","author":"Mohamed","year":"2022","journal-title":"Value Health"},{"key":"2024112123540250800_ciae336-B25","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciab698","article-title":"Remdesivir and mortality in patients with coronavirus disease 2019","volume":"74","author":"Diaz","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024112123540250800_ciae336-B26","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe COVID-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112123540250800_ciae336-B27","doi-asserted-by":"crossref","first-page":"e4166","DOI":"10.1093\/cid\/ciaa1041","article-title":"Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care","volume":"73","author":"Olender","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024112123540250800_ciae336-B28","doi-asserted-by":"crossref","first-page":"ofab278","DOI":"10.1093\/ofid\/ofab278","article-title":"Remdesivir versus standard-of-care for severe coronavirus disease 2019 infection: an analysis of 28-day mortality","volume":"8","author":"Olender","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024112123540250800_ciae336-B29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat Assoc"},{"key":"2024112123540250800_ciae336-B30","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2024112123540250800_ciae336-B31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2024112123540250800_ciae336-B32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.mayocp.2020.11.024","article-title":"COVID-19: understanding inter-individual variability and implications for precision medicine","volume":"96","author":"Pereira","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2024112123540250800_ciae336-B33","doi-asserted-by":"crossref","first-page":"e2244505","DOI":"10.1001\/jamanetworkopen.2022.44505","article-title":"Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States","volume":"5","author":"Chokkalingam","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024112123540250800_ciae336-B34","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1093\/cid\/ciab1035","article-title":"Real-world effectiveness of remdesivir in adults hospitalized with coronavirus disease 2019 (COVID-19): a retrospective, multicenter comparative effectiveness study","volume":"75","author":"Garibaldi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024112123540250800_ciae336-B35","doi-asserted-by":"crossref","first-page":"40095","DOI":"10.57187\/smw.2023.40095","article-title":"Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis","volume":"153","author":"Estill","year":"2023","journal-title":"Swiss Med Wkly"},{"key":"2024112123540250800_ciae336-B36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/EDE.0000000000001598","article-title":"Effectiveness of remdesivir treatment protocols among patients hospitalized with COVID-19: a target trial emulation","volume":"34","author":"Breskin","year":"2023","journal-title":"Epidemiology"},{"key":"2024112123540250800_ciae336-B37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/23744235.2023.2187081","article-title":"Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone","volume":"55","author":"Leding","year":"2023","journal-title":"Infect Dis (Lond)"},{"key":"2024112123540250800_ciae336-B38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(22)00528-8","article-title":"Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"11","author":"Amstutz","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024112123540250800_ciae336-B39","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/v14081706","article-title":"The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Lai","year":"2022","journal-title":"Viruses"},{"key":"2024112123540250800_ciae336-B40","doi-asserted-by":"crossref","first-page":"E969","DOI":"10.1503\/cmaj.220471","article-title":"Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis","volume":"194","author":"Pitre","year":"2022","journal-title":"CMAJ"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae336\/58662263\/ciae336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/5\/1182\/60779453\/ciae336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/5\/1182\/60779453\/ciae336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T23:55:00Z","timestamp":1732233300000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/5\/1182\/7699414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,26]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae336","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,15]]},"published":{"date-parts":[[2024,6,26]]}}}